



WHO WE ARE

Biomere is a preclinical CRO based in Worcester, MA providing a personalized and customer-focused approach to drug discovery delivering our clients with innovative, timely and cost-efficient solutions.

FACILITY

Our newly renovated, state-of-the-art preclinical facilities include over 70,000 square feet of space supporting a wide variety of programs performed in rodents to NHPs. Our small animal program includes a "shower in" barrier facility as well as procedure rooms and resources dedicated to support our client's programs. We are staffed with a team of outstanding technical and professional scientists working in a culture and atmosphere of partnership and collaboration that is focused on customer service.

GRANTS/ACCREDITATIONS

Unique in the industry, Biomere's scientific expertise has been recognized by awards of over \$26MM in USPHS grants and contracts.

Biomere has maintained an Assurance of Compliance with OLAW since 1999, AAALAC-accreditation since 2006, and has been registered with the USDA since 2008.

STAFF

The success of our recent expansion has resulted in significant growth to where Biomere now has close to 70 full-time employees. Senior management includes veterans of the drug development and CRO industries. Our scientists are complimented by six full-time veterinarians that in collaboration with our technical teams are experienced in conducting simple to complex projects for our Sponsors.

STUDIES

Since 2014, Biomere has used thousands of rodents in hundreds of studies across a variety of therapeutic areas. Biomere's non-human primate program was launched in 2011 with the acquisition of a breeding colony of marmosets. Since then, Biomere has expanded the NHP program to include macaques including both rhesus and cynomolgus monkeys, as well. With a dedicated team of experts and our unique approach, the program has grown rapidly to include general, dedicated and specialized colonies of naïve and non-naïve animals, including a colony of CSF ported animals. We collect and ship thousands of samples annually. We are experienced in standard as well as novel routes of administration including intratracheal, intrathecal, intra-articular, intravitreal, nebulization and intracranial. 2017 will bring continued expansion of the NHP program as additional capacity is brought on-line in Q1 to help meet demand. Our animal behavior and enrichment program is a standard in the industry and paramount to the success of our NHP program. All of our studies in rodents and NHPs have focused on discovery-based services including but not limited to efficacy, toxicology, pharmacokinetics, pharmacodynamics, ADME in normal and disease models.



PHARMACOLOGY MODELS

AUTOIMMUNE DISEASE

Type 1 Diabetes
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Inflammatory bowel disease
Multiple Sclerosis
Graft-versus-host disease

NEURO-DEGENERATIVE DISEASE

Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Neuropathies
Encephalopathies
Transgenic rat models of CNS

METABOLIC DISEASE

Type 2 Diabetes
Metabolic Syndrome (Obesity and diabetic complications)

INFLAMMATION AND PAIN

Delayed Type Hypersensitivity
Osteoarthritis
Lipopolysaccharides (LPS)
Capsaicin
Formalin

NUCLEIC ACID PROGRAMS

ROA (Intraarticular, Intrathecal, Intravitreal, Intratracheal)
Aerosol (Microsprayer, Nebulizer)

VIROLOGY

Virus Infection
Vaccines/Antiviral

OPHTHAMOLOGY

Dry Eye
Glaucoma
AMD
Allergy